Published in Dig Dis Sci on February 01, 1998
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut (1999) 1.59
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res (2007) 1.13
Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08
Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology (2004) 1.01
Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int J Cancer (2007) 1.00
A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev (2009) 1.00
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol (2013) 0.94
Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice. J Nutr Biochem (2011) 0.87
Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2005) 0.87
CXCR4 in Cancer and Its Regulation by PPARgamma. PPAR Res (2008) 0.85
Cytosolic phospholipase A2-p11 interaction controls arachidonic acid release as a function of epithelial cell confluence. Biochem J (2004) 0.84
Colorectal cancer: update on recent advances and their impact on screening protocols. J Natl Med Assoc (2000) 0.79
Effects of adenovirus-mediated human cyclooxygenase-2 antisense RNA on the growth of hepatocellular carcinoma. World J Gastroenterol (2005) 0.75
Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer (2017) 0.75
Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget (2016) 0.75
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 2.43
Sulindac for polyposis of the colon. J Surg Oncol (1983) 2.34
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 1.86
Rectal cancer in FAP patient after sulindac. Lancet (1994) 1.80
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res (1996) 1.77
Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut (1994) 1.72
Prostaglandins from tumours of human large bowel. Br J Cancer (1977) 1.58
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (1993) 1.54
Prostaglandins and cancer: an update. Prostaglandins (1974) 1.43
Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology (1994) 1.39
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32
Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res (1997) 1.28
Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins (1981) 1.18
Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med (1991) 1.16
Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum (1990) 1.13
Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J Pharmacol Exp Ther (1979) 1.09
Investigation of colonic prostaglandins in carcinogenesis in the rat colon. Dis Colon Rectum (1991) 1.04
Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue. Surg Forum (1971) 1.01
Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep (1980) 0.99
Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J Pharmacol Exp Ther (1977) 0.98
A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol (1988) 0.97
Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. Biochem Pharmacol (1979) 0.91
Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol Biomarkers Prev (1995) 0.89
Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinomas and normal human lung by capillary gas chromatography-negative ion chemical ionization mass spectrometry. Prostaglandins (1986) 0.88
[Investigation of endogenous prostaglandins in DMH induced colonic cancer in rats]. Nihon Shokakibyo Gakkai Zasshi (1985) 0.85
Profiling of bisenoic prostaglandins and thromboxane B2 in bronchoalveolar fluid from the lower respiratory tract of human subjects by combined capillary gas chromatography-mass spectrometry. Prostaglandins (1988) 0.84
Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum (1996) 0.83
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun (1985) 6.57
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev (1989) 5.59
Allelotype of colorectal carcinomas. Science (1989) 5.54
Identification and characterization of a gene encoding a gut-enriched Krüppel-like factor expressed during growth arrest. J Biol Chem (1996) 5.52
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med (1994) 5.12
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med (1997) 4.66
Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994) 4.43
Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res (1987) 4.25
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Clonal analysis of human colorectal tumors. Science (1987) 3.72
Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (1985) 3.72
A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences. Proc Natl Acad Sci U S A (1981) 3.68
Identification of p53 gene mutations in bladder cancers and urine samples. Science (1991) 3.68
The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology (1992) 3.59
Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science (1992) 3.58
Mismatch repair deficiency in phenotypically normal human cells. Science (1995) 3.55
Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci U S A (2001) 3.51
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
The biology of the mammalian Krüppel-like family of transcription factors. Int J Biochem Cell Biol (2001) 3.31
The APC gene product in normal and tumor cells. Proc Natl Acad Sci U S A (1993) 3.25
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res (1995) 3.13
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem (2000) 3.02
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Ischemic injury in the cat small intestine: role of superoxide radicals. Gastroenterology (1982) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med (1998) 2.91
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77
Krüppel-like factor 4 (gut-enriched Krüppel-like factor) inhibits cell proliferation by blocking G1/S progression of the cell cycle. J Biol Chem (2001) 2.71
An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol (1994) 2.67
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66
Molecular determinants of dysplasia in colorectal lesions. Cancer Res (1994) 2.62
Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol (1997) 2.57
Mad-related genes in the human. Nat Genet (1996) 2.51
Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science (1985) 2.49
hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res (1994) 2.39
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol (1987) 2.31
Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA (1989) 2.29
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Identification of the DNA sequence that interacts with the gut-enriched Krüppel-like factor. Nucleic Acids Res (1998) 2.23
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Desmoid tumours in familial adenomatous polyposis. Gut (1994) 2.08
Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology (1984) 2.08
Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery (1987) 2.07
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A (1991) 2.07
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Intestinal-enriched Krüppel-like factor (Krüppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem (2001) 2.01
Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol (1987) 1.97
Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst (1993) 1.94
Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol (1997) 1.93
Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol (1996) 1.91
Two potent nuclear localization signals in the gut-enriched Krüppel-like factor define a subfamily of closely related Krüppel proteins. J Biol Chem (1997) 1.91
Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut (1996) 1.89
CpG island methylation in colorectal adenomas. Am J Pathol (2001) 1.88
Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology (2000) 1.86
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 1.86
Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut (1993) 1.85
Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut (1998) 1.85
Morphology of single ganglion cells in the glaucomatous primate retina. Invest Ophthalmol Vis Sci (1998) 1.81
Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child (1991) 1.81